Breast Cancer Res Treat:饮酒并不会增加BRCA1和BRCA2突变基因携带者乳腺癌的风险

2015-05-08 范伟译 MedSci原创

背景:一般人群中酒精对女性乳腺癌的发展是有不利影响的,我们评估在BRCA1或BRCA2基因突变的女性中的这种关联是否也类似的存在。方法:每日酒精消耗量的相关基线信息来自对前瞻性研究组招募的3067 BRCA突变携带者进行的调查问卷。每两年进行一次女性随访调查,直到最后随访问卷的日期,乳腺癌的诊断日期、侧乳预防性切除的日期或死亡日期。Cox比例风险模型用来评估相对风险(RRs),95%置信区间(CI

背景:一般人群中酒精对女性乳腺癌的发展是有不利影响的,我们评估在BRCA1或BRCA2基因突变的女性中的这种关联是否也类似的存在。

方法:每日酒精消耗量的相关基线信息来自对前瞻性研究组招募的3067 BRCA突变携带者进行的调查问卷。每两年进行一次女性随访调查,直到最后随访问卷的日期,乳腺癌的诊断日期、侧乳预防性切除的日期或死亡日期。Cox比例风险模型用来评估相对风险(RRs),95%置信区间(CIs)用来评测浸润性乳腺癌与酒精消耗或先于完成基线调查问卷之间的联系。


结果:在平均5.4年的随访后,我们观察到259例主要浸润性乳腺癌发病病例。相比未饮酒者,曾经饮酒者调整的相对风险RRs为1.06(95% CI  0.78 - 1.44),当前饮酒者为1.08(0.79 - 1.47)。对于女性最高与最低的五分位数的累积饮酒量,相对风险RR为0.94(95% CI  0.63 - 1.40;P趋势 = 0.65)。

结论:我们的研究表明,饮酒并不是引起BRCA1或BRCA2基因突变女性乳腺癌的危险因素。

原始出处:

Cybulski C1, Lubinski J, Huzarski T, Lynch HT, Randall SA,et al.Prospective 
evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat. 2015 May 3.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-06-29 yige2014
  2. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-10-21 qblt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    期待有更多研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-05-10 zhaojie88
  7. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-05-10 TZF0810
  10. [GetPortalCommentsPageByObjectIdResponse(id=1715649, encodeId=a2711e1564947, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Mon Jun 29 14:21:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710798, encodeId=cc9e1e107980b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Mar 04 19:21:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004900, encodeId=2978200490093, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Oct 21 21:21:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35099, encodeId=1aed3509902, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:09:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796242, encodeId=e07a1e9624206, content=<a href='/topic/show?id=cf2a1e7818c' target=_blank style='color:#2F92EE;'>#TREAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17781, encryptionId=cf2a1e7818c, topicName=TREAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sun Nov 22 19:21:00 CST 2015, time=2015-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351069, encodeId=2aac1351069d6, content=<a href='/topic/show?id=12e43e1263' target=_blank style='color:#2F92EE;'>#Breast#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3712, encryptionId=12e43e1263, topicName=Breast)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423290, encodeId=ebdb142329072, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593986, encodeId=32bc159398671, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602836, encodeId=b3d816028361d, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618075, encodeId=5fa316180e5ad, content=<a href='/topic/show?id=4271e550237' target=_blank style='color:#2F92EE;'>#突变基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75502, encryptionId=4271e550237, topicName=突变基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bf319833427, createdName=ms1490123962508630, createdTime=Sun May 10 03:21:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]

相关资讯

BMJ:饮酒少者心血管系统更健康

酒精脱氢酶1B基因(ADH1B)的多态性rs1229984 认为与饮酒有关,也认为这是酒精与心血管疾病关系的分子基础。但是以往研究考虑较少。最新一项基于孟尔随随机的meta分析,荟萃了56个流行病学研究数据,合计261991个欧洲人群,其中20259例患者合并冠脉疾病,10164位患者伴有卒中事件。结果发现,与非携带者相比,A-allele of ADH1B rs1229984携带者每周

BMJ:工作狂,当心饮酒过量

近日,英国医学期刊(BMJ)发表的一项研究显示,每周工作超过48小时的人群比那些按标准时长工作的员工存在更多过度饮酒的问题。 这里所说的“过度饮酒”(有风险的酒精摄入,Risky alcohol consumption)是指女性每周饮酒超过14个标准单位,或男性每周饮酒超过21个标准单位的情况(注:该研究采用的是英国标准,每个标准单位相当于8克或10毫升酒精)。一般认为,超过这个限度的酒精摄入会

最坑爹饮酒有益的十四大谎言

红酒被很多人都认为养颜延缓衰老的佳品。其实,不管是什么酒,是有害或者有益关键还在于控制饮用量。最新一项大型科学研究显示:中年人饮酒引发中风的危害堪比高血压和糖尿病(见:Stroke:饮酒增加卒中风险堪比高血压、糖尿病 )。当然,也有研究显示,微量饮酒(注意:微量)可能真有益健康(见:BMJ:饮酒少者心血管系统更健康),但总体来说,还是弊大于利(见:饮酒对大脑影响利弊谈)。今天就让小编来给大家说

Journal of Hepatology:哪种饮酒模式容易得肝硬化?

酒精是导致酒精性肝硬化最主要的病因,但较少人知道饮酒模式的意义,哪种饮酒模式更容易得肝硬化呢?来自丹麦的研究人员进行了这样一项有趣,同时又贴近生活的研究,该项研究成果发表在近期的Journal of Hepatology 方法 我们在丹麦从1993年到2011年期间关于肿瘤、饮食、健康研究中的55917例参与者(年龄50岁-64岁)中调查了酒精性肝硬化的危险因素。基线信息通过问卷获得,包括酒精

Diabetes Care:2型糖尿病患者适度饮酒或有益于心血管

一项多国联合研究表明,适度饮酒(尤其是葡萄酒)的2型糖尿病患者与心血管事件或全因死亡风险降低有相关性。研究由乔治全球健康研究院牵头,相关论文2月27日在线发表于《糖尿病护理》(Diabetes Care)杂志。 适度饮酒与死亡和冠状动脉疾病风险减少具有相关性,而2型糖尿病患者的心血管健康和饮酒的相关性尚未明了。该研究的研究者们评估了ADVANCE试验参与者饮酒带来的影响。主要终点为心血管事件(心

Neurology:老年男性规律适量饮酒降低认知损害风险

酒精中毒损害注意力、精神运动速度、跟踪能力、工作记忆和认知灵活性,但是慢性应用酒精对认知的结果还没有定论;基于此,西澳大学的Osvaldo P. Almeida教授发表文章表明:在老年男性中规律适量饮酒降低认知损害风险。 这篇文章回顾性分析社区居住的65-83岁的老年男性3542人,并随访6年。参与者提供详细的前一年酒精使用情况,分为戒酒组、偶尔饮酒组、和规律饮酒组:轻度(每周饮酒<15)、